News & Events about Corcept Therapeutics Inc.
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ: CORT) investors that the firm has initiated an investigation into possible...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT) for violations of the securities laws. The investigation focuses on whether the Company...
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the ...
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the ...
Ticker Report
3 months ago
Corcept Therapeutics Incorporated (NASDAQ:CORT Get Rating) insider Sean Maduck sold 25,000 shares of the firms stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $25.64, for a total value of $641,000.00. Following the transaction, the insider...